SEC Form 4 · accession 0001209191-15-066702
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen LaHue Cartt
Director
Period of report
Aug 14, 2015
Accepted (ET)
Aug 18, 2015 · 6:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1 | Aug 14, 2015 | P | 18,400 | $2.6498 | A | 98,525 | D | |
| Common Shares, no par valueF2 | Aug 17, 2015 | P | 39,400 | $2.8294 | A | 137,925 | D | |
| Common Shares, no par valueF3 | Aug 18, 2015 | P | 17,200 | $2.8972 | A | 155,125 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF4 | $3.57 | holding | — | — | — | — | Jun 30, 2020 | Common Shares | 20,000 | 20,000 | D |
| Option to Purchase Common SharesF5 | $3.43 | holding | — | — | — | — | Nov 3, 2019 | Common Shares | 20,000 | 20,000 | D |
Explanation of responses
- F1The price of $2.6498 per share represents a weighted average of prices ranging from $2.63 to $2.679 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F2The price of $2.8294 per share represents a weighted average of prices ranging from $2.69 to $2.99 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F3The price of $2.8972 per share represents a weighted average of prices ranging from $2.86 to $3.00 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F4Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2015 based upon continued service on the board of directors.
- F55,000 options became exercisable on December 31, 2014; March 31, 2015; and June 30, 2015. The remaining 5,000 options will become exercisable on September 30, 2015 based upon continued service on the board of directors.